Soto, 1,418 patient HCQ late treatment study: 6% higher mortality [p=0.46] https://c19p.org/sotoh
copied to clipboard
Mortality and associated risk factors in patients hospitalized due to COVID-19 in a Peruvian reference hospital
et al., PLOS ONE, doi:10.1371/journal.pone.0264789
Retrospective 1,418 very late stage (46% mortality) patients in Peru, showing no significant difference with HCQ. There is strong confounding by indication, for example 48% of patients with baseline SpO2 <70% were treated compared with 22% for SpO2 >95%. There may also be significant confounding by time with SOC changing substantially over the first few months of the pandemic.
|
risk of death, 6.0% higher, HR 1.06, p = 0.46, treatment 292 of 590 (49.5%), control 362 of 828 (43.7%), Cox proportional hazards.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details, substantial unadjusted confounding by indication likely, substantial confounding by time possible due to significant changes in SOC and treatment propensity near the start of the pandemic.
Soto et al., 2 Mar 2022, retrospective, Peru, peer-reviewed, median age 58.0, 10 authors, study period April 2020 - August 2020, dosage not specified.
Late treatment
is less effective
is less effective
soto
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.